[-] Show simple item record

dc.contributor.authorElliott, Tricia C.eng
dc.contributor.authorMontoya, Cathy C.eng
dc.date.issued2008eng
dc.description.abstractEvidence is conflicting with regard to the comparative frequency of venous thrombolic events (VTE) among women using the transdermal patch when compared to an oral contraceptive (OC), even though the patch produces a relatively high serum ethinyl estradiol (EE) level (strength of recommendation [SOR]: C, conflicting cohort case-control studies). The vaginal ring has a risk of VTE comparable to that of an OC (SOR: B, 1 comparative study).eng
dc.identifier.urihttp://hdl.handle.net/10355/3785eng
dc.languageEnglisheng
dc.publisherFamily Physicians Inquiries Networkeng
dc.relation.ispartofcollectionClinical Inquiries, 2008 (MU)eng
dc.relation.ispartofcommunityUniversity of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Networkeng
dc.relation.ispartofseriesJournal of family practice, 57, no. 10 (October 2008): 680+.eng
dc.rightsOpenAccess.eng
dc.rights.licenseThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.eng
dc.subjectestrogen exposureeng
dc.subjectthromboembolic diseaseeng
dc.subjectcontraceptioneng
dc.subject.lcshOral contraceptives -- Side effectseng
dc.subject.lcshContraceptives, Vaginaleng
dc.subject.lcshTransdermal medication -- Side effectseng
dc.subject.lcshThrombosiseng
dc.titleHow does VTE risk for the patch and vaginal ring compare with oral contraceptives?eng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record